APGE (Apogee Therapeutics) Beginning Cash Position: $131.55 Mil (As of Mar. 2026)


APGE Apogee Therapeutics Inc APGE
12 GF Score
Price $133.65
! 3 Warning Signs
View Full Analysis

What is Apogee Therapeutics Beginning Cash Position?

Apogee Therapeutics APGE +0.06% 12 Beginning Cash Position is $131.55 Mil as of Mar. 2026. GuruFocus rates APGE with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Apogee Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $131.55 Mil.

Apogee Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 ($124.49 Mil) to Dec. 2025 ($107.91 Mil) but then increased from Dec. 2025 ($107.91 Mil) to Mar. 2026 ($131.55 Mil).

Apogee Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($151.89 Mil) to Dec. 2024 ($118.61 Mil) but then increased from Dec. 2024 ($118.61 Mil) to Dec. 2025 ($142.08 Mil).

Apogee Therapeutics Beginning Cash Position Related Terms

Apogee Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Apogee Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apogee Therapeutics Beginning Cash Position Chart

Apogee Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
-0.00 151.89 118.61 142.08

Apogee Therapeutics Quarterly Data
Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.08 107.21 124.49 107.91 131.55
APGE
12GF Score
Apogee Therapeutics Inc APGE
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apogee Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $131.55 Mil mean?
Apogee Therapeutics (APGE) has a Beginning Cash Position of $131.55 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Apogee Therapeutics and its competitors.
Is Apogee Therapeutics' Beginning Cash Position too high?
Apogee Therapeutics' current Beginning Cash Position is $131.55 Mil. Overall, Apogee Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Apogee Therapeutics' Beginning Cash Position compare to NUVL and CORT?
Apogee Therapeutics' Beginning Cash Position of $131.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Apogee Therapeutics and its competitors. Apogee Therapeutics's current Beginning Cash Position is $131.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apogee Therapeutics stock overvalued right now?
Apogee Therapeutics (APGE) has a current Beginning Cash Position of $131.55 Mil. The current Beginning Cash Position is $131.55 Mil. Apogee Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Apogee Therapeutics (APGE), the current Beginning Cash Position is $131.55 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apogee Therapeutics Business Description

Address 221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
12GF Score

Get the complete analysis for APGE

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$133.65
Price